Mr Ez Aldeen Esawi
Higher Degree by Research Candidate
School of Pharmacy and Biomedical Sciences
College of Health
I’m a PhD candidate in the Prostate Cancer Research Group at South Australian immunoGENomics Cancer Institute (SAiGENCI) supervised by Dr. Zeyad Nassar and led by Professor Lisa Butler. My research focuses on understanding the molecular mechanisms driving advanced prostate cancer progression, with a particular interest in lipid metabolism, androgen receptor signalling, and lineage plasticity leading to neuroendocrine prostate cancer. Using integrative genomic and molecular approaches, I investigate how metabolic reprogramming contributes to therapy resistance and aggressive disease phenotypes. My work aims to identify novel therapeutic targets and improve treatment strategies for advanced prostate cancer patients.
| Date | Position | Institution name |
|---|---|---|
| 2019 - 2023 | Research assistance | University of Jordan |
| 2017 - 2023 | Medical laboratory technologist | King Hussein Cancer Center |
| Language | Competency |
|---|---|
| Arabic | Can read, write, speak, understand spoken and peer review |
| English | Can read, write, speak and understand spoken |
| Date | Institution name | Country | Title |
|---|---|---|---|
| 2018 - 2021 | University of Jordan | Jordan | M.Sc. Medical laboratory sciences |
| 2013 - 2017 | Hashemite University | Jordan | BSc |
| Year | Citation |
|---|---|
| 2026 | Shirazi, S., Esawi, E., Nassar, Z. D., Gronthos, S., & Cakouros, D. (2026). Hyperglycemia Leads to BMSC Impaired Osteogenesis, Enhanced Adipogenesis, and Altered Metabolism. Journal of Cellular Biochemistry, 127(4), e70090-1-e70090-11. Scopus2 WoS2 Europe PMC1 |
| 2025 | Mahmoud, I. S., Hyari, H., Esawi, E., & Alshaer, W. (2025). Anti-tumour signalling pathways and molecular targets of 1,4-naphthoquinone-based natural dyes. Natural Product Research, 1-20. Scopus4 |
| 2025 | Mahmoud, I. S., Nsairat, H., Alsotari, S., Jaber, A., Esawi, E., Abdelnabi, H., . . . Odeh, F. (2025). Thymoquinone chemically conjugated to doxorubicin: antitumor activity and subcellular localization. Rsc Advances, 15(45), 38176-38188. Scopus3 WoS2 Europe PMC2 |
| 2024 | Alkhawaja, B., Abuarqoub, D., Al-Natour, M., Alshaer, W., Abdallah, Q., Esawi, E., . . . Watts, A. G. (2024). Facile Rebridging Conjugation Approach to Attain Monoclonal Antibody-Targeted Nanoparticles with Enhanced Antigen Binding and Payload Delivery. Bioconjugate Chemistry, 35(10), 1491-1502. Scopus7 WoS7 Europe PMC2 |
| 2023 | Nsairat, H., Alshaer, W., Odeh, F., Esawi, E., Khater, D., Bawab, A. A., . . . Mubarak, M. S. (2023). Recent advances in using liposomes for delivery of nucleic acid-based therapeutics. Opennano, 11, 100132. Scopus108 |
| 2023 | Alshaer, W., Nsairat, H., Lafi, Z., Hourani, O. M., Al-Kadash, A., Esawi, E., & Alkilany, A. M. (2023). Quality by Design Approach in Liposomal Formulations: Robust Product Development. Molecules, 28(1), 19 pages. Scopus91 WoS74 Europe PMC44 |
| 2023 | Abuarqoub, D., Mahmoud, N., Alshaer, W., Mohammad, M., Ibrahim, A. A., Al-Mrahleh, M., . . . Awidi, A. (2023). Biological Performance of Primary Dental Pulp Stem Cells Treated with Gold Nanoparticles. Biomedicines, 11(9), 1-15. Scopus3 WoS3 Europe PMC3 |
| 2023 | Niemi, M. E. K., Karjalainen, J., Liao, R. G., Neale, B. M., Daly, M., Ganna, A., . . . Sedaghati-Khayat, B. (2023). Erratum to: Mapping the human genetic architecture of COVID-19 (Nature, (2021), 600, 7889, (472-477), 10.1038/s41586-021-03767-x). Nature, 621(7977), E7-E26. Scopus92 WoS104 Europe PMC101 |
| 2023 | Esawi, E. I., Mahmoud, I. S., Abdullah, M. S., Abuarqoub, D. A., Ahram, M. A., & Alshaer, W. M. (2023). 1,4-Naphthoquinone Induces FcRn Protein Expression and Albumin Recycling in Human THP-1 Cells. ACS Omega, 8(18), 16491-16499. Scopus4 WoS3 Europe PMC2 |
| 2022 | Al-Azzawi, H., Alshaer, W., Esawi, E., Lafi, Z., Abuarqoub, D., Zaza, R., . . . Awidi, A. (2022). Multifunctional nanoparticles recruiting hyaluronic acid ligand and polyplexes containing low molecular weight protamine and ATP-Sensitive DNA motif for doxorubicin delivery. Journal of Drug Delivery Science and Technology, 69, 11 pages. Scopus10 WoS7 |
| 2022 | The COVID-19 Host Genetics Initiative., & Ganna, A. (2022). A second update on mapping the human genetic architecture of COVID-19. Europe PMC3 |
| 2021 | Esawi, E., Alshaer, W., Mahmoud, I. S., Alqudah, D. A., Azab, B., & Awidi, A. (2021). Aptamer-Aptamer Chimera for Targeted Delivery and ATP-Responsive Release of Doxorubicin into Cancer Cells. International Journal of Molecular Sciences, 22(23), 12940. Scopus21 WoS22 Europe PMC16 |
| 2021 | Sweidan, N., Esawi, E., Ismail, M., & Alshaer, W. (2021). Anticancer Cardenolides from the aerial parts of Calortopis procera. Zeitschrift Fur Naturforschung Section C Journal of Biosciences, 76(5), 243-250. Scopus5 WoS5 Europe PMC3 |
| 2021 | Mahmoud, I. S., Hatmal, M. M., Abuarqoub, D., Esawi, E., Zalloum, H., Wehaibi, S., . . . Alshaer, W. (2021). 1,4-Naphthoquinone Is a Potent Inhibitor of IRAK1 Kinases and the Production of Inflammatory Cytokines in THP-1 Differentiated Macrophages. ACS Omega, 6(39), 25299-25310. Scopus32 WoS29 Europe PMC20 |
| 2020 | Odeh, F., Nsairat, H., Alshaer, W., Ismail, M. A., Esawi, E., Qaqish, B., . . . Ismail, S. I. (2020). Aptamers chemistry: Chemical modifications and conjugation strategies. Molecules, 25(1), 51 pages. Scopus364 WoS326 Europe PMC249 |
| Year | Citation |
|---|---|
| 2022 | Esawi, E., Nsairat, H., Mahmoud, I. S., Lafi, Z., Al-Kadash, A., Al-Ragheb, B. A., . . . Alhaer, W. (2022). Clinical use and future perspective of aptamers. In Aptamers Engineered Nanocarriers for Cancer Therapy (pp. 481-520). Elsevier. DOI Scopus9 |
| 2022 | Nsairat, H., Alshaer, W., Mahmoud, I. S., Ismail, M. A., Esawi, E., Alsotari, S., & Ismail, S. I. (2022). Aptamers in Theranostic Bionanomaterials. In Bionanotechnology Next Generation Therapeutic Tools (pp. 130-158). BENTHAM SCIENCE PUBLISHERS. DOI Scopus1 |
Connect With Me
External Profiles
